摘要 |
A combination comprising a compound of Formula (I):
or a pharmaceutically acceptable salt thereof;
and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective ²-adrenoceptor and ± 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors. |
申请人 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
发明人 |
BROOKS, Carl;CHEUNG, Mui;EIDAM, Hilary, Schenck;GOODMAN, Krista, B.;HAMMOND, Marlys;HILFIKER, Mark, A.;HOANG, Tram, H.;PATTERSON, Jaclyn, R.;STOY, Patrick;YE, Guosen |